Effector Total Liab vs Cash Analysis

EFTR Stock  USD 0.0002  0.00  0.00%   
Effector Therapeutics financial indicator trend analysis is much more than just examining Effector Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Effector Therapeutics is a good investment. Please check the relationship between Effector Therapeutics Total Liab and its Cash accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.

Total Liab vs Cash

Total Liab vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Effector Therapeutics Total Liab account and Cash. At this time, the significance of the direction appears to have very week relationship.
The correlation between Effector Therapeutics' Total Liab and Cash is 0.28. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash in the same time period over historical financial statements of Effector Therapeutics, assuming nothing else is changed. The correlation between historical values of Effector Therapeutics' Total Liab and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Effector Therapeutics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Liab i.e., Effector Therapeutics' Total Liab and Cash go up and down completely randomly.

Correlation Coefficient

0.28
Relationship DirectionPositive 
Relationship StrengthVery Weak

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Cash

Cash refers to the most liquid asset of Effector Therapeutics, which is listed under current asset account on Effector Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Effector Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Effector Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.
Most indicators from Effector Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 12/12/2025, Sales General And Administrative To Revenue is likely to grow to 3.47, though Enterprise Value Over EBITDA is likely to grow to (1.04).
 2022 2023 2024 2025 (projected)
Interest Expense2.3M2.9M3.4M2.1M
Depreciation And Amortization53K111K99.9K104.8K

Effector Therapeutics fundamental ratios Correlations

0.71-0.12-0.320.950.88-0.79-0.840.30.410.940.330.920.821.00.770.990.60.231.0-0.410.8-0.88-0.320.820.82
0.710.320.420.510.93-0.68-0.32-0.290.830.560.450.850.380.710.930.660.88-0.210.70.320.97-0.61-0.510.970.96
-0.120.320.48-0.330.050.470.26-0.260.14-0.160.83-0.14-0.1-0.13-0.02-0.120.08-0.99-0.130.460.230.5-0.010.130.13
-0.320.420.48-0.460.150.050.7-0.750.58-0.510.140.01-0.43-0.320.28-0.40.39-0.5-0.320.990.30.25-0.20.270.26
0.950.51-0.33-0.460.73-0.76-0.870.50.170.890.170.830.90.950.650.940.370.420.95-0.540.65-0.87-0.080.690.7
0.880.930.050.150.73-0.84-0.52-0.160.770.730.330.980.560.880.950.830.880.050.870.050.95-0.82-0.520.970.97
-0.79-0.680.470.05-0.76-0.840.570.06-0.64-0.710.21-0.91-0.46-0.8-0.88-0.75-0.75-0.56-0.790.13-0.740.970.44-0.8-0.8
-0.84-0.320.260.7-0.87-0.520.57-0.570.03-0.95-0.14-0.6-0.73-0.84-0.44-0.88-0.22-0.37-0.840.76-0.440.710.02-0.47-0.48
0.3-0.29-0.26-0.750.5-0.160.06-0.57-0.690.370.12-0.030.670.3-0.240.35-0.550.30.3-0.74-0.16-0.140.45-0.15-0.14
0.410.830.140.580.170.77-0.640.03-0.690.260.110.69-0.060.410.80.350.97-0.090.410.510.73-0.51-0.780.750.73
0.940.56-0.16-0.510.890.73-0.71-0.950.370.260.240.790.710.940.640.970.490.280.94-0.60.64-0.82-0.280.670.67
0.330.450.830.140.170.330.21-0.140.120.110.240.20.430.320.150.330.14-0.790.320.10.430.13-0.050.350.36
0.920.85-0.140.010.830.98-0.91-0.6-0.030.690.790.20.630.920.940.880.820.240.92-0.080.9-0.92-0.480.930.94
0.820.38-0.1-0.430.90.56-0.46-0.730.67-0.060.710.430.630.810.420.80.10.170.81-0.490.54-0.610.150.540.56
1.00.71-0.13-0.320.950.88-0.8-0.840.30.410.940.320.920.810.770.990.60.251.0-0.410.79-0.88-0.320.820.82
0.770.93-0.020.280.650.95-0.88-0.44-0.240.80.640.150.940.420.770.720.890.120.770.190.95-0.81-0.450.980.97
0.990.66-0.12-0.40.940.83-0.75-0.880.350.350.970.330.880.80.990.720.560.240.99-0.490.74-0.85-0.320.760.77
0.60.880.080.390.370.88-0.75-0.22-0.550.970.490.140.820.10.60.890.560.00.60.30.82-0.66-0.760.840.83
0.23-0.21-0.99-0.50.420.05-0.56-0.370.3-0.090.28-0.790.240.170.250.120.240.00.24-0.5-0.12-0.59-0.05-0.03-0.03
1.00.7-0.13-0.320.950.87-0.79-0.840.30.410.940.320.920.811.00.770.990.60.24-0.410.79-0.88-0.320.820.82
-0.410.320.460.99-0.540.050.130.76-0.740.51-0.60.1-0.08-0.49-0.410.19-0.490.3-0.5-0.410.210.33-0.150.170.16
0.80.970.230.30.650.95-0.74-0.44-0.160.730.640.430.90.540.790.950.740.82-0.120.790.21-0.7-0.361.01.0
-0.88-0.610.50.25-0.87-0.820.970.71-0.14-0.51-0.820.13-0.92-0.61-0.88-0.81-0.85-0.66-0.59-0.880.33-0.70.4-0.76-0.76
-0.32-0.51-0.01-0.2-0.08-0.520.440.020.45-0.78-0.28-0.05-0.480.15-0.32-0.45-0.32-0.76-0.05-0.32-0.15-0.360.4-0.39-0.37
0.820.970.130.270.690.97-0.8-0.47-0.150.750.670.350.930.540.820.980.760.84-0.030.820.171.0-0.76-0.391.0
0.820.960.130.260.70.97-0.8-0.48-0.140.730.670.360.940.560.820.970.770.83-0.030.820.161.0-0.76-0.371.0
Click cells to compare fundamentals

Effector Therapeutics Account Relationship Matchups

Effector Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets16.7M54.1M29.1M20.5M23.6M27.6M
Short Long Term Debt Total13.0M20.0M20.3M20.5M23.6M19.6M
Other Current Liab82K3.0M2.9M2.9M3.4M2.6M
Total Current Liabilities8.8M4.0M25.1M25.8M29.7M18.2M
Total Stockholder Equity979K17.3M3.9M(5.8M)(6.7M)(6.3M)
Property Plant And Equipment Net126K257K352K193K173.7K280.2K
Net Debt(2.3M)(29.7M)11.6M5.7M6.5M6.8M
Retained Earnings(136.7M)(120.9M)(143.6M)(179.4M)(161.4M)(169.5M)
Accounts Payable347K516K1.5M2.3M2.7M2.8M
Cash15.2M49.7M8.7M14.9M17.1M20.2M
Non Current Assets Total126K1.2M1.1M706K811.9K853.2K
Non Currrent Assets Other(126K)903K711K513K590.0K619.4K
Cash And Short Term Investments15.2M49.7M26.3M18.4M21.1M24.9M
Common Stock Shares Outstanding598.6K1.6M1.6M2.2M2.5M1.3M
Liabilities And Stockholders Equity16.7M54.1M29.1M20.5M23.6M27.6M
Other Current Assets1.4M3.2M1.7M1.4M1.6M1.9M
Other Stockholder Equity4.5M138.2M147.5M347.2M399.2M419.2M
Total Liab148.9M36.8M25.2M26.3M23.7M41.0M
Total Current Assets16.6M52.9M28.0M19.8M22.8M26.8M
Short Term Debt6.0M88K20.2M20.5M23.6M13.7M

Additional Tools for Effector Stock Analysis

When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.